Expanding studies of biofilm
A meeting held in 1996 at Hotel Hyatt in Monterey, a small city on the seashore down south of San Francisco, has become an epoch-making event in the dental field. The reason is that this was the first international meeting taking up "biofilm" as the theme. The main symposist was Dr. Costerton, University of Iowa, USA (1) . On the day of the meeting I foresaw that the era of biofilm would present itself in the 21st century. Just before it, Dr. Costerton published a review article on biofilm in Science , in which he introduced dental caries and periodontal disease regarding it as biofilm infection (Table 1) (2) . It may safely be said that the study of biofilm expanded worldwide with this paper as the turning point. Now in our country the concept that dental caries and periodontal disease are biofilm infections seems to have been established certainly among dental colleges and even in commercial messages in TV programs.
Periodontal disease as a biofilm infection
In the periodontal pocket of periodontal disease as a biofilm infection, there is a condition in which periodontopathic bacteria form a film-like colony by adherence and aggregation using cementum as a foothold ( Fig. 1 ) (3) . In the periodontal pocket, there are a few hundred kinds of bacteria, which seem to amount to more than several hundred millions in number. The situation is as if it was the inside of a germ culture flask. Within a biofilm the numbers of bacteria are stratified three dimensionally, and metabolic products of bacteria, oxygen partial pressure, pH, and nutrients are unevenly distributed ( Fig. 2 ) (4) . In other words, the biofilm offers an environment inhospitable for bacteria. Nonetheless, bacteria form biofilms to protect themselves from attacks by immunocytes and antibacterial agents in the external environment. The biofilm plays a role as a protective barrier for bacteria.
In the case of periodontal disease, a biofilm is formed by periodontopathic bacteria in the periodontal pocket (Fig. 3) . Bacteria released from the biofilm float in the pocket and then attach to and invade into gingival epithe-lium. Continuous stimulation by bacteria inflicts injury within the gingiva, destroys the local immune system, and activates osteoclasts in the tissue. Thus, periodontal disease makes progress (5).
Thinking over therapy of biofilm
When a biofilm is formed in the periodontal pocket, effects of mechanical removal and antibiotics are attenuated. The sustained local drug delivery system (LDDS) to inject a tetracycline agent commonly used clinically (minocycline hydrochloride ointment for dental use) into the periodontal pocket is considered to have antibacterial potency particularly to floating bacteria released from the biofilm. By means of this method, the sustained-release of antibacterial agents acts for a long time in high concentrations. However, tetracycline antibiotics do not invade into the biofilm and cannot destroy it (6) .
On the other hand, macrolide agents exert no antibacterial action to Pseudomonas aeruginosa , for example, but have a wide-spectrum antibacterial activity, showing such a pharmacological effect as inhibition of biofilm formation and bacterial adherence. In addition, glycocalyx, a constituent of biofilm derived from Pseudomonas aeruginosa , is decomposed by macrolide antibiotics. This effect has been suggested to be attributed to their high permeability into the biofilm and the inhibition of polysaccharide production due to inhibition of GMD (guanosine diphosphomannose dehydrogenase) in the glycocalyx-producing system within bacteria (7). On the basis of molecular structure, macrolide antibiotics are broadly classified into 14-, 15-, and 16-membered ring groups according to the number of atoms forming the lactone ring (Fig. 4) . Fourteen-and fourteen-membered ring macrolides are used as the basic agents in continuous therapy during the remission period. In the exacerbation period, on the contrary, a temporary combined use of antibacterial agents effective on respective pathogenic bacteria is considered to be a useful therapy at present. In fact, in diffuse panbronchiolitis caused by biofilmforming bacteria, macrolide agents with a 14-membered ring, clarithromycin, and a 15-membered ring, azithromycin, dissolve the biofilm, and they have already been established as an effective therapy (8) .
Since these macrolide agents are capable of dissolving the biofilm, we assumed that they would be effective in treatments of periodontal disease as a biofilm infection (Fig. 5) .
Development of in vitro model of biofilm (9)
In the basic experiment, first of all, we sought drugs capable of dissolving the biofilm. In the oral cavity, when glycoproteins derived from saliva and exudates in the gingival sulcus are absorbed to the surface of the teeth and the pellicle (acquired pellicle) is formed, various kinds of bacteria adhere to the pellicle. At present, the bacteria binding to the surface of teeth have been identified. Accordingly, we cultivated Streptococcus gordonii , which is involved in initial adherence to the dental surface, under anaerobic condition on a hydroxyapatite disk processed with saliva. In addition, we cocultivated a representative periodontopathic bacterium, Porphyromonas gingivalis, and thus developed an in vitro model of biofilm (Fig. 6 ). In this model we studied the effects of the tetracycline antibiotic minocycline and the macrolide antibiotics azithromycin, clarithromycin, and josamycin by observing morphological changes in the biofilm with a scanning electron microscope. Our results confirmed that erythromycin and azithromycin have potency to dissolve the biofilm (Fig. 7) .
Clinical study of combined application of azithromycin in early onset (aggressive) periodontitis (10)
Early onset (aggressive) periodontitis develops before 35 years of age. Because of rapid destruction of the periodontal tissue, it is a morbid condition with a possibility of early loss of teeth. Accordingly, the progress of the periodontal disease must be inhibited as early as pos- sible. At present, tetracycline, amoxicillin, and metronidazole are administered as a combined drug application therapy, but the reports on the effects of macrolide antibiotics are restricted. The macrolide antibiotic azithromycin exerts antibacterial action to a wide variety of intraoral bacteria. Furthermore, it was reported that azithromycin was taken up into phagocytes and was released into the inflamed tissue for a long period of time. Accordingly, we performed a clinical study to investigate the effects of azithromycin as an adjunctive therapy in non-operative treatments of early onset (aggressive) periodontitis. Figure 8 illustrates the sequence of treatments using azithromycin. A case report is shown below. Chief complaints: Feeling that her teeth are loosened and separation of the maxillary anterior teeth.
Past history: A few years ago the maxillary anterior teeth began to separate from one another. Since the lacunae gradually became enlarged, she visited an orthodontist and was referred to a specialist of periodontal disease. No particular systemic diseases were noticed in the past history.
Clinical diagnosis: Early onset (aggressive) periodontitis (diffuse type).
Therapeutic strategy: i) Thorough practice of basic treatments of periodontal disease and professional mechanical tooth cleaning (PMTC), ii) administration of antibiotics (azithromycin), and iii) orthodontic treatments.
Course of treatments:
1) First examination: Separation (flare-out) was noticed among the maxillary anterior teeth, and swelling and reddening were found in the gingiva. Periodontal pocket (mean PD): 3.9 mm. bleeding on probing (POB): 78%. Proportion of pockets deeper than 4 mm (pocket rate, PoR): 55.4%.
2) Periodontal treatments: Thorough mouth cleaning and completion of basic periodontal treatments by scaling and root planing. After confirming that the gingival index (GI) was improved to less than 1 and that mouth cleaning was daily carried on, we combined administration of an antibiotic (azithromycin, 500 mg/day for 3 days) during the basic periodontal treatment period. In this case we administered it once 5 months after the first examination. PMTC was carried out every 2 weeks along with an approach under infiltration anesthesia (root planing) as the countermeasure for the vertical bone defect.
3) Reevaluation: The periodontal tissue was improved so much that the condition of stable periodontal tissue endurable for dynamic migration of teeth was prepared for orthodontic treatments in response to her chief complaint. PD: 2.8 mm. BOP: 29%. PoR: 22.6%. 4) Orthodontic treatments: Since there was a possibility for orthodontic appliances to facilitate adherence of biofilm during orthodontic treatments, we tried to stabilize the periodontal tissue by PMTC (orthodontic treatments were performed by Dr. Ikue Watanabe, Omni- dentics, Sapporo). 5) Maintenance period: By orthodontic treatments, remission of her chief complaints was gained and stable periodontal tissue was established. Thus, treatments were successfully completed with the patient's high satisfaction. PD: 2.0 mm. BOP: 8%. PoR: 3%.
Results and discussion
We studied the effects of azithromycin as an adjunctive therapy of non-operative treatments of early onset (aggressive) periodontitis. After 2 -3 months of guidance for oral cleaning, scaling, and root planning as basic treatments, azithromycin was administered (500 mg/day for 3 days). PMTC was made at the pace of once every 2 weeks during the period of treatments of periodontal disease. When GI reached less than 1, we judged that the initial treatments were completed. Clinical parameters PD, BOP, and PoR were improved (Fig. 10) . The period of treatments of the azithromycin-administered group (5 cases: 1 male and 4 female subjects, 29.6 years of age on the average) was 4.7 ± 3.2 months, while in the group who received similar basic treatments but did not receive azithromycin, the period of treatments (6 cases, 2 male and 4 female subjects, 26.5 years of age on the average) was 11.2 ± 4.9 months (Table 2) . Thus, in the azithromycin-administered group a remarkably improving effect was revealed for the treatment period.
The best feature of azithromycin is its excellent entry into the tissue, especially into the inflamed tissue. Furthermore, since its half-time in the serum and tissue is as long as 60 -80 h, satisfactory clinical effects can be obtained with its administration once a day for 3 days. According to the basic theory of pharmacodynamics, there are two possibilities in the route of action of antibiotics administered systemically: either they enter the tissue by infiltrating from the capillaries in the periodontal tissue and affect the periodontopathic bacteria or they destroy the biofilm by the effects of the agents exuding into the periodontal pocket (Fig. 11) . In future, more novel therapies will be developed by regarding periodontal disease as a biofilm infection.
Conclusion: drugs are not the first choice for periodontal treatments
Control of biofilm is a universal treatment as the basis of dental care in general. It consists of active removal and prevention of biofilm by dental professionals with specialized tools on the basis of practice of daily oral cleaning by the patients themselves. It is only for such restricted cases as early onset (aggressive) periodontitis The duration of the initial preparation was significantly shortened when combined with administration of azithromycin. Modified from Ref. 9 . that we have established the therapy of systemic administration of antibiotics like a treatment resistant periodontitis. In contrast, there are several reports that azithromycin was used for the treatment of chronic periodontitis. However, regimens of azithromycin administration were different among these reports (Table 3 ) (10 -15). There- fore, the establishment of guidelines for azithromycin administration is needed. The key to successful treatments is the basic treatment of periodontal disease in collaboration with patients, however. Therefore, the first choice of periodontal treatments is not administration of drugs. Even if we combine drugs, we cannot inhibit the progress of periodontal disease if we do not succeed in basic treatments of periodontal disease. The effect of drugs is always inextricably linked with their side effects. Recently, as seen in "consciousness disorder after taking the antibiotic telithromycin", "convulsion caused by combined use of new quinolone antibiotics and non-steroid antibiotics", and in addition, the problem of "MRSA", there are some antibiotics that are no longer effective due to prevailing resistant bacteria.
In conclusion, at present, we consider that the combination of antibiotics is recommended in chronic (but not acute) periodontitis only when initial preparation is fully performed but inflammation remains.
